Pharmacophore refinement of gpIIb/IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides

SummaryStructurally guided design approaches to low-molecular-weight platelet aggregation antagonists addressing the platelet-associated heterodimeric cell surface receptor gpIIb/IIIa rely on comparative studies of an ensemble of conformationally and biologically characterized compounds, since no high-resolution structure of the receptor system is available. We report a classical indirect and comparative pharmacophore refinement approach based on a series of small cyclic Arg-Gly-Asp (RGD) peptides as gpIIb/IIIa-fibrinogen interaction antagonists. These peptides have previously been investigated as potent and selective tumor cell adhesion inhibitors. The definition of geometrical descriptors classifying the RGD peptide conformations and their subsequent analysis over selected RGD- and RXD-containing protein structures allows for a correlation of distinct structural features for platelet aggregation inhibition. An almost parallel alignment of the Arg and Asp side chains was identified by a vector analysis as being present in all active cyclic hexa-and pentapeptides. This orientation is induced mainly by the constraint of backbone cyclization and is not of any covalent tripeptide-inherent origin, which was rationalized by a 500 ps high-energy MD simulation of a sequentially related linear model peptide. The incorporation of the recognition tripeptide Arg-Gly-Asp into the cyclic peptide templates acted as a filter mechanism, restricting the otherwise free torsional relation of both side chains to a parallel orientation. Based on the derived results, several detailed features of the receptor binding site could be deduced in terms of receptor complementarity. These findings should govern the design of next-generation compounds with enhanced activities. Furthermore, the complementary stereochemical characteristics of the substrate can be used as boundary conditions for pseudoreceptor modelling studies that are capable of reconstructing a hypothetical binding pocket, qualitatively resembling the steric and electronic demands of gpIIb/IIIa. It is interesting to note that these features provide clear differentiation to requirements for inhibition of % MathType!MTEF!2!1!+-% feaafiart1ev1aaatCvAUfeBSjuyZL2yd9gzLbvyNv2CaerbuLwBLn% hiov2DGi1BTfMBaeXatLxBI9gBaerbd9wDYLwzYbItLDharqqtubsr% 4rNCHbGeaGqiVu0Je9sqqrpepC0xbbL8F4rqqrFfpeea0xe9Lq-Jc9% vqaqpepm0xbba9pwe9Q8fs0-yqaqpepae9qq-f0-yqaqVeLsFr0-vr% 0-vr0db8meaabaqaciGacaGaaeqabaWaaeaaeaaakeaacaqGXoWaaS% baaSqaaiaabAfadaWgaaadbaaabeaaaSqabaGccaqGYoWaaSbaaSqa% aiaaiodaaeqaaaaa!3DDC!\[{\text{\alpha }}_{{\text{V}}_{} } {\text{\beta }}_3 \] substrate binding. This can account for the extremely high selectivity and activity of some of our constrained peptides for either the % MathType!MTEF!2!1!+-% feaafiart1ev1aaatCvAUfeBSjuyZL2yd9gzLbvyNv2CaerbuLwBLn% hiov2DGi1BTfMBaeXatLxBI9gBaerbd9wDYLwzYbItLDharqqtubsr% 4rNCHbGeaGqiVu0Je9sqqrpepC0xbbL8F4rqqrFfpeea0xe9Lq-Jc9% vqaqpepm0xbba9pwe9Q8fs0-yqaqpepae9qq-f0-yqaqVeLsFr0-vr% 0-vr0db8meaabaqaciGacaGaaeqabaWaaeaaeaaakeaacaqGXoWaaS% baaSqaaiaab+bbcaqGIbaabeaakiaabk7adaWgaaWcbaGaaG4maaqa% baaaaa!3E56!\[{\text{\alpha }}_{{\text{b}}} {\text{\beta }}_3 \] or the % MathType!MTEF!2!1!+-% feaafiart1ev1aaatCvAUfeBSjuyZL2yd9gzLbvyNv2CaerbuLwBLn% hiov2DGi1BTfMBaeXatLxBI9gBaerbd9wDYLwzYbItLDharqqtubsr% 4rNCHbGeaGqiVu0Je9sqqrpepC0xbbL8F4rqqrFfpeea0xe9Lq-Jc9% vqaqpepm0xbba9pwe9Q8fs0-yqaqpepae9qq-f0-yqaqVeLsFr0-vr% 0-vr0db8meaabaqaciGacaGaaeqabaWaaeaaeaaakeaacaqGXoWaaS% baaSqaaiaabAfaaeqaaOGaaeOSdmaaBaaaleaacaaIZaaabeaaaaa!3DA4!\[{\text{\alpha }}_{\text{V}} {\text{\beta }}_3 \] receptor.

[1]  W. DeGrado,et al.  Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library , 1992, Proteins.

[2]  A. Lender,et al.  Design and synthesis of sulfur-free cyclic hexapeptides which contain the RGD sequence and bind to the fibrinogen GP IIb/IIIa receptor. A conformation-based correlation between propensity for imide formation and receptor affinity. , 2009, International journal of peptide and protein research.

[3]  R F Standaert,et al.  Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex , 1991, Science.

[4]  J. Devlin,et al.  Random peptide libraries: a source of specific protein binding molecules. , 1990, Science.

[5]  G. Poste,et al.  Development of GPIIb/IIIa antagonists as antithrombotic drugs. , 1992, Trends in pharmacological sciences.

[6]  R. Timpl,et al.  Integrin and Arg-Gly-Asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI. , 1993, Experimental cell research.

[7]  R. Timpl,et al.  Dynamic Forcing, a Method for Evaluating Activity and Selectivity Profiles of RGD (Arg‐Gly‐Asp) Peptides , 1992 .

[8]  L Wang,et al.  Peptoids: a modular approach to drug discovery. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Calvo,et al.  SK&F 106760: Reinstatement of high receptor affinity in a peptide fragment (RGDS) of a large glycoprotein (fibrinogen) through conformational constraints , 1991 .

[10]  I. Charo,et al.  Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. , 1993, The Journal of biological chemistry.

[11]  S. Lam,et al.  Evidence that arginyl-glycyl-aspartate peptides and fibrinogen gamma chain peptides share a common binding site on platelets. , 1987, The Journal of biological chemistry.

[12]  Y. Hata,et al.  Structure of rice ferricytochrome c at 2.0 A resolution. , 1983, Journal of molecular biology.

[13]  D. Veber,et al.  NMR and molecular modeling characterization of RGD containing peptides. , 2009, International journal of peptide and protein research.

[14]  R. Alon,et al.  Structural analysis of integrin recognition and the inhibition of integrin-mediated cell functions by novel nonpeptidic surrogates of the Arg-Gly-Asp sequence. , 1993, Biochemistry.

[15]  L. Delbaere,et al.  Refined structure of alpha-lytic protease at 1.7 A resolution. Analysis of hydrogen bonding and solvent structure. , 1985, Journal of molecular biology.

[16]  K. Lam,et al.  A new type of synthetic peptide library for identifying ligand-binding activity , 1992, Nature.

[17]  F. Felici,et al.  Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. , 1991, Journal of molecular biology.

[18]  R. Barrett,et al.  Peptides on phage: a vast library of peptides for identifying ligands. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Pitti,et al.  Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Jung,et al.  Multiple Peptide Synthesis Methods and Their Applications. New Synthetic Methods (87) , 1992 .

[21]  D C Carter,et al.  Crystal structure of Azotobacter cytochrome c5 at 2.5 A resolution. , 1985, Journal of molecular biology.

[22]  D. Egan,et al.  NMR studies of [U-13C]cyclosporin A bound to cyclophilin: bound conformation and portions of cyclosporin involved in binding. , 1994, Biochemistry.

[23]  C. Rossi,et al.  Inhibition of murine melanoma cell-matrix adhesion and experimental metastasis by albolabrin, an RGD-containing peptide isolated from the venom of Trimeresurus albolabris. , 1991, Experimental cell research.

[24]  E Ruoslahti,et al.  Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Bennett,et al.  The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. , 1985, The Journal of biological chemistry.

[26]  R J Gould,et al.  Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. , 1988, The Journal of biological chemistry.

[27]  C. Damsky,et al.  Cell-to-cell contact and extracellular matrix: Editorial overview , 1990 .

[28]  J Engel,et al.  Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. , 1994, The Journal of biological chemistry.

[29]  G. Müller,et al.  βVI Turns in peptides and proteins: A model peptide mimicry , 1993 .

[30]  D. Osguthorpe,et al.  Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase‐trimethoprim, a drug‐receptor system , 1988, Proteins.

[31]  R. Houghten,et al.  Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery , 1991, Nature.

[32]  W. G. Richards Computer-aided molecular design. , 1988 .

[33]  Kenneth M. Yamada,et al.  Adhesive recognition sequences. , 1991, The Journal of biological chemistry.

[34]  C. Beddell,et al.  The Design of drugs to macromolecular targets , 1992 .

[35]  Horst Kessler,et al.  Conformation and Biological Activity of Cyclic Peptides , 1982 .

[36]  P. Hadváry,et al.  Low molecular weight, non-peptide fibrinogen receptor antagonists. , 1992, Journal of medicinal chemistry.

[37]  S. Niewiarowski,et al.  Trigramin: primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human platelets. , 1989, Biochemistry.

[38]  Stuart L. Schreiber,et al.  Natural Products as Probes of Cellular Function: Studies of Immunophilins , 1992 .

[39]  V. Saudek,et al.  Three-dimensional structure of echistatin, the smallest active RGD protein. , 1991, Biochemistry.

[40]  R. Cooke,et al.  Nuclear magnetic resonance studies of the snake toxin echistatin. 1H resonance assignments and secondary structure. , 1991, European journal of biochemistry.

[41]  M. Humphries,et al.  The molecular basis and specificity of integrin-ligand interactions. , 1990, Journal of cell science.

[42]  Richard O. Hynes,et al.  Integrins: A family of cell surface receptors , 1987, Cell.

[43]  D E Tronrud,et al.  Structural analysis of the inhibition of thermolysin by an active-site-directed irreversible inhibitor. , 1983, Biochemistry.

[44]  V. Garsky,et al.  Echistatin is a potent inhibitor of bone resorption in culture , 1990, The Journal of cell biology.

[45]  C. E. Peishoff,et al.  Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptides. , 1992, Journal of medicinal chemistry.

[46]  M. Polokoff,et al.  Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans. , 1989, The Journal of biological chemistry.

[47]  C. E. Peishoff,et al.  Conformations of Arg-Gly-Asp containing heterodetic cyclic peptides: solution and crystal studies , 1992 .

[48]  E. Ruoslahti,et al.  Effects of modifications of the RGD sequence and its context on recognition by the fibronectin receptor. , 1989, The Journal of biological chemistry.

[49]  S. Roberts,et al.  Molecular recognition : chemical and biochemical problems II , 1992 .

[50]  v Claassen,et al.  Trends in drug research , 1993 .

[51]  Ronald Breslow,et al.  Molecular recognition , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Timpl,et al.  Arg‐Gly‐Asp constrained within cyclic pentapoptides Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 , 1991, FEBS letters.

[53]  H. Kessler,et al.  Calculation of Molecular Dynamics for Peptides in Dimethyl Sulfoxide: Elimination of Vacuum Effects , 1992 .

[54]  C. L. Propst,et al.  Computer-Aided Drug Design: Methods and Applications , 1989 .

[55]  S. Niewiarowski,et al.  Elegantin and albolabrin purified peptides from viper venoms: homologies with the RGDS domain of fibrinogen and von Willebrand factor. , 1990, Biochimica et biophysica acta.

[56]  E. Ruoslahti,et al.  Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides [published erratum appears in J Cell Biol 1989 Jun;108(6):following 2546] , 1988, The Journal of cell biology.

[57]  I. Kuntz Structure-Based Strategies for Drug Design and Discovery , 1992, Science.

[58]  J. Maraganore,et al.  Binding of the snake venom-derived proteins applaggin and echistatin to the arginine-glycine-aspartic acid recognition site(s) on platelet glycoprotein IIb.IIIa complex inhibits receptor function. , 1990, The Journal of biological chemistry.

[59]  J. Tschopp,et al.  Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists. , 1994, Journal of medicinal chemistry.

[60]  J. Newman,et al.  Novel RGD analogs as antithrombotic agents , 1991 .

[61]  V J Hruby,et al.  Conformational restrictions of biologically active peptides via amino acid side chain groups. , 1982, Life sciences.

[62]  S. Timmons,et al.  Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. , 1984, Biochemistry.

[63]  K Wüthrich,et al.  The NMR structure of cyclosporin A bound to cyclophilin in aqueous solution. , 1991, Biochemistry.

[64]  Graeme Wistow,et al.  X-ray analysis of the eye lens protein γ-II crystallin at 1·9 Å resolution , 1983 .

[65]  Bernard Maigret,et al.  Computational simulations of the conformational behaviour of the adhesive proteins RGDS fragment , 1992, J. Comput. Aided Mol. Des..

[66]  R. Timpl,et al.  Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. , 1992, European journal of biochemistry.

[67]  M. Ginsberg,et al.  Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. , 1991, Trends in biochemical sciences.

[68]  R. Calvo,et al.  Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. , 1991, Journal of medicinal chemistry.

[69]  L. Verlet Computer "Experiments" on Classical Fluids. I. Thermodynamical Properties of Lennard-Jones Molecules , 1967 .

[70]  K. Chan,et al.  Cyclic RGD peptide analogues as antiplatelet antithrombotics. , 1992, Journal of medicinal chemistry.

[71]  C. E. Peishoff,et al.  Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonists. , 1992, Journal of medicinal chemistry.

[72]  G. Wagner,et al.  Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist. , 1991, Science.

[73]  Erkki Ruoslahti,et al.  Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule , 1984, Nature.

[74]  W A Hendrickson,et al.  Structure of a fibronectin type III domain from tenascin phased by MAD analysis of the selenomethionyl protein. , 1992, Science.

[75]  Horst Kessler,et al.  Peptoids—A New Approach to the Development of Pharmaceuticals , 1993 .

[76]  C. E. Peishoff,et al.  Conformational analysis of cyclic hexapeptides containing the D-Pro-L-Pro sequence to fix .beta.-turn positions , 1992 .

[77]  C. Basson,et al.  Biologically active Arg-Gly-Asp oligopeptides assume a type II beta-turn in solution. , 1993, Biochemistry.

[78]  E Ruoslahti,et al.  New perspectives in cell adhesion: RGD and integrins. , 1987, Science.

[79]  C. Dalvit,et al.  1H NMR studies of echistatin in solution. Sequential resonance assignments and secondary structure. , 1991, European journal of biochemistry.

[80]  J. Scott,et al.  Searching for peptide ligands with an epitope library. , 1990, Science.

[81]  S. Albelda,et al.  Integrins and other cell adhesion molecules , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[82]  Stuart L. Schreiber,et al.  Atomic Structure of the Rapamycin Human Immunophilin FKBP-12 Complex , 1991 .

[83]  Peter D. Kwong,et al.  Crystal structure of an HIV-binding recombinant fragment of human CD4 , 1990, Nature.